Clinical manifestation | OR (manifestation before/at cohort inclusion) | OR (new manifestation) | OR (manifestation during follow up) |
---|---|---|---|
Alopecia* | 0.79 (0.61–1.02) | 1.35 (0.92–1.98) | 1.08 (0.83–1.42) |
Oral/nasal ulcers* | 0.81 (0.62–1.04) | 1.05 (0.66–1.69) | 0.74 (0.53–1.03) |
Photosensitivity* | 0.79 (0.62–1.03) | 0.63 (0.39–1.04) | 0.81 (0.60–1.09) |
Subacute cutaneous lupus* | 1.21 (0.57–2.54) | 0.81 (0.31–2.13) | 0.7 (0.30–1.62) |
Malar rash* | 0.92 (0.71–1.18) | 1.41 (0.91–2.16) | 1.17 (0.89–1.52) |
Discoid lesions* | 1.24 (0.82–1.88) | 1.83 (0.81–4.11) | 1.29 (0.77–2.18) |
Any of the previous* | 0.88 (0.64–1.23) | 1.32 (1.00–1.75) | 1.23 (0.95–1.59) |
*Outcome: Daily solar radiation increment of 1 Kwh/m2/day. All regressions adjusted for age at onset, gender, ethnic group, urban residence, latitude, antimalarial use and autoantibodies (anti DNA, anti Sm, anti Ro, antiphospholipid, low C3).